Of course, the details of ongoing ICH discussions cannot be shared publicly until they are authorized for disclosure.
One thing that caught my attention was @SSimon’s comment during the Q&A session at the Fiscal Year 2026 Generic Drug Science and Research Initiatives Public Workshop. She mentioned that the Error-Corrected Sequencing (ECS) spectra for NDEA and N-nitroso-bisoprolol were quite different.
Recent discussions on read-across have also highlighted that surrogate selection should consider not only structural similarity but also physicochemical properties, pharmacokinetics (PK), and structural features or mechanisms relevant to toxicity.
I hope that, as these aspects become better understood and systematically evaluated, a framework for establishing acceptable intake limits for NDSRIs that are negative in in vivo mutagenicity studies will also emerge.
Let’s keep an eye on how this discussion develops.